Journal
NATURE MEDICINE
Volume 18, Issue 2, Pages 307-314Publisher
NATURE RESEARCH
DOI: 10.1038/nm.2617
Keywords
-
Funding
- Chinese National Basic Research Programs [2011CB910602]
- Hong Kong Competitive Earmarked Research Grant [CUHK479111, 473011]
- Faculty of Medicine of the Chinese University of Hong Kong [2041478, 2041525]
- Hong Kong Baptist University [31-08-089]
- Chinese National Natural Science Foundation [30830029]
- National Key Technologies Research and Development Program for New Drugs [2009ZX09503-002]
Ask authors/readers for more resources
Metabolic skeletal disorders associated with impaired bone formation are a major clinical challenge. One approach to treat these defects is to silence bone-formation-inhibitory genes by small interference RNAs (siRNAs) in osteogenic-lineage cells that occupy the niche surrounding the bone-formation surfaces. We developed a targeting system involving dioleoyl trimethylammonium propane (DOTAP)-based cationic liposomes attached to six repetitive sequences of aspartate, serine, serine ((AspSerSer)(6)) for delivering siRNAs specifically to bone-formation surfaces. Using this system, we encapsulated an osteogenic siRNA that targets casein kinase-2 interacting protein-1 (encoded by Plekho1, also known as Plekho1). In vivo systemic delivery of Plekho1 siRNA in rats using our system resulted in the selective enrichment of the siRNAs in osteogenic cells and the subsequent depletion of Plekho1. A bioimaging analysis further showed that this approach markedly promoted bone formation, enhanced the bone micro-architecture and increased the bone mass in both healthy and osteoporotic rats. These results indicate (AspSerSer)(6)-liposome as a promising targeted delivery system for RNA interference- based bone anabolic therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available